# Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

Source: https://onco.cc/trials/nct04888312/  
OnCo record `nct04888312` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CD40 agonist mitazalimab in combination with chemotherapy in pancreatic ductal adenocarcinoma, run by Alligator Bioscience AB, active and no longer recruiting.

## Summary

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients is a phase 1/2 interventional study registered as NCT04888312 by Alligator Bioscience AB, with 94 participants enrolled, started 2021-09-17 and due to reach its primary completion in 2026-06-01. Interventions recorded: CD40 agonist mitazalimab in combination with chemotherapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04888312
- Phase: 1/2
- Setting: An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Sponsor: Alligator Bioscience AB
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT04888312: https://clinicaltrials.gov/study/NCT04888312

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Mitazalimab](https://onco.cc/drugs/mitazalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct04888312.json